Bringing The Clinician's Rationale Into The Heart Of Strategic Decision-Making At Boston Scientific

Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.

IV1809_Finger-Frame_176026316_1200.jpg
• Source: Shutterstock

Boston Scientific Corp. has lit up the health care industry news pages arguably more than any other blue chip global medtech over the past 15 years – hugely acquisitive in 2004-2005, entering neuomodulation, working at the cutting edge of cardiovascular implant technology, stretching and stretching again to bring in Guidant in 2006, watching the share price dip below $5 in mid-2012, making ex-J&J's Mike Mahoney CEO in 2012, watching the share price recover, buying Vessix Vascular and Bard EP, and since spring 2018, bringing seven more innovative companies into the group.

Alongside organic R&D, M&A is clearly very important to Boston's growth, a fact that Ian Meredith, MD, PhD, appreciated long...

More from Leadership

More from In Vivo